---
title: Simple Surgical Glove Compression to Prevent Chemotherapy-Induced Peripheral Neuropathy
nct_id: NCT07169864
overall_status: NOT_YET_RECRUITING
phase: NA
sponsor: Jinsong Lu
study_type: INTERVENTIONAL
primary_condition: Breast Cancer
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07169864.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07169864"
ct_last_update_post_date: 2025-09-12
last_seen_at: "2026-05-12T07:23:27.984Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Simple Surgical Glove Compression to Prevent Chemotherapy-Induced Peripheral Neuropathy

**Official Title:** An Exploratory Self-Controlled Study on the Preventive Effect of the Simple Surgical Glove Compression Technique Against Chemotherapy-Induced Peripheral Neuropathy

**NCT ID:** [NCT07169864](https://clinicaltrials.gov/study/NCT07169864)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 44
- **Lead Sponsor:** Jinsong Lu
- **Conditions:** Breast Cancer, Chemotherapy Induced Peripheral Neuropathy (CIPN), Neoadjuvant Therapy
- **Start Date:** 2025-09-15
- **Completion Date:** 2027-12-31
- **CT.gov Last Update:** 2025-09-12

## Brief Summary

To evaluate the preventive efficacy of a simple surgical glove compression technique in reducing the incidence and severity of Chemotherapy Induced Peripheral Neuropathy among patients receiving chemotherapy.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age ≥ 18 years;
* Histologically confirmed primary invasive breast cancer;
* Planned to receive ≥ 8 weeks of weekly neoadjuvant chemotherapy (utidelone plus cisplatin);
* ECOG performance status: 0-1;

Exclusion Criteria:

* Distant metastasis;
* Presence of sensory or motor neurological disorders, or symptoms related to peripheral neuropathy with CTCAE grade ≥ 2, or currently receiving medication for peripheral neuropathy;
* Conditions affecting limb function;
* Known allergy to glove materials (e.g., latex)
```

## Arms

- **Group with surgical glove compression applied to the dominant hand** (EXPERIMENTAL)

## Interventions

- **Simple Surgical Glove Compression Technique** (PROCEDURE) — Patients will wear surgical gloves of smaller size than the patient's hand, on the dominant hand from 15 minutes before the start of each neoadjuvant chemotherapy infusion until 15 minutes after the end of infusion (total of 90 minutes). The non-dominant hand will serve as the untreated control.

## Primary Outcomes

- **Change in the functional assessment of cancer therapy/gynaecologic oncology group-neurotoxicity (FACT/GOG-Ntx) subscale score(range:-44to44; higher scores indicate better neurotoxicity-related quality of life).** _(time frame: From baseline (prior to neoadjuvant chemotherapy) to after 8 weeks of neoadjuvant chemotherapy in breast cancer)_

## Secondary Outcomes

- **Change in scores and the sum score of four hand-related items of the FACT/GOG-Ntx subscale (range: -16to+16; higher scores indicate better neurotoxicity-related quality of life).** _(time frame: From baseline (prior to neoadjuvant chemotherapy) to after 8 weeks of neoadjuvant chemotherapy in breast cancer)_
- **The overall change in the FACT/GOG-Ntx subscale score (range: -44to44; higher scores indicate better neurotoxicity-related quality of life)** _(time frame: From baseline to the end of neoadjuvant chemotherapy and 6 months after completion of neoadjuvant chemotherapy)_
- **Incidence of CIPN as determined by changes in tactile sensitivity assessed with the Semmes-Weinstein monofilament test** _(time frame: From baseline to the end of and 6 months after completion of neoadjuvant chemotherapy)_
- **Incidence of CIPN according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0** _(time frame: From baseline to the end of and 6 months after completion of neoadjuvant chemotherapy)_
- **Changes in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) scores (range: -12to12, higher scores on functional and global health domains indicate better quality of life,; -84to84; while higher** _(time frame: At baseline (prior to initiation of neoadjuvant chemotherapy), at 8 weeks of neoadjuvant chemotherapy, at 2 weeks after completion of neoadjuvant chemotherapy, and at 6 months after completion of neoadjuvant chemotherapy.)_
- **Changes in the maximum width and height of the lunula of each finger** _(time frame: At baseline (prior to initiation of neoadjuvant chemotherapy), at 8 weeks of neoadjuvant chemotherapy, at 2 weeks after completion of neoadjuvant chemotherapy, and at 6 months after completion of neoadjuvant chemotherapy.)_

## Locations (1)

- Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.renji hospital, school of medicine, shanghai jiaotong university|shanghai||china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07169864.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07169864*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*